Clinical development of PD-1 in advanced melanoma Journal Article

Authors: Munhoz, R. R.; Postow, M. A.
Article Title: Clinical development of PD-1 in advanced melanoma
Abstract: The development of new treatment options has dramatically improved the landscape for patients with advanced melanoma. Part of these advances emerged through the identification of the importance of factors that regulate the immune system, including proteins that negatively modulate T cell-mediated responses termed "immune checkpoints." Indeed, blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint served as a proof of principle that the manipulation of these molecules could induce robust anticancer effects, yet limited to a small percentage of patients. Targeting a distinct checkpoint, the PD-1 yielded improved outcomes and reduced toxicity compared with CTLA-4 blockade and, in separate studies, chemotherapy. More recently, combined CTLA-4/PD-1 blockade was shown to result in higher response rates, while accompanied by increased toxicity. In this article, we review the clinical development of anti-PD-1 monotherapy and combinations that may expand the benefit of immunotherapy for patients with advanced melanoma. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: unclassified drug; fatigue; review; placebo; advanced cancer; diarrhea; drug efficacy; drug withdrawal; monotherapy; side effect; paclitaxel; temozolomide; carboplatin; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; ipilimumab; cancer immunotherapy; melanoma; pruritus; rash; immunotherapy; lactate dehydrogenase; hypothyroidism; pd-1; central nervous system metastasis; randomized controlled trial (topic); clinical trial (topic); thyroiditis; nivolumab; human; priority journal; pembrolizumab; immune-checkpoint blockade; antineoplastic monoclonal antibody; programmed cell death protein 1 antibody
Journal Title: The Cancer Journal
Volume: 24
Issue: 1
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2018-01-01
Start Page: 7
End Page: 14
Language: English
DOI: 10.1097/ppo.0000000000000299
PROVIDER: scopus
PMCID: PMC5819364
PUBMED: 29360722
Notes: Review -- Export Date: 1 March 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Michael Andrew Postow
    185 Postow